Revenue was 10 million yen, operating loss was approximately 161,406 thousand yen, cumulative interim net loss was approximately 154,997 thousand yen, and the full-year forecast remains unchanged. R&D expenses increased; progress reported on clinical trials related to AI medical device and RS5614. Cash at the end of the interim period was 3,193,623 thousand yen, and the equity ratio was 96.7%. The financial summary includes forward-looking statements.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4889","jir_company_name":"Renascience Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4889-20261111-01.pdf","jir_short_summary":"Revenue was 10 million yen, operating loss was approximately 161,406 thousand yen, cumulative interim net loss was approximately 154,997 thousand yen, and the full-year forecast remains unchanged. R&D expenses increased; progress reported on clinical trials related to AI medical device and RS5614. Cash at the end of the interim period was 3,193,623 thousand yen, and the equity ratio was 96.7%. The financial summary includes forward-looking statements.","jir_summary":"### Business Performance Summary\nRenascience Inc. announced its second quarter financial summary. Interim period revenue was 10 million yen, operating loss was 161,406 thousand yen, ordinary loss was 154,495 thousand yen, and interim net loss was 154,997 thousand yen. Research and development expenses amounted to 76,282 thousand yen, mainly due to continued investment in oncology, anti-aging areas, and development of AI program medical devices. Cash and cash equivalents were 3,193,623 thousand yen, net assets were 3,167,679 thousand yen, and the equity ratio remained at a high level. The company has made no changes to previously announced forward-looking estimates.\n\n### Outlook and Strategy\nThe company will continue a portfolio strategy utilizing multiple modalities. Clinical trials, including earlier- and later-stage studies for RS5614 in the oncology field, are progressing. Research and development in anti-aging and longevity areas will continue, and efforts to implement AI program medical devices in society will be advanced. The company plans to expand clinical trial progress and future business opportunities through international collaborative research and AMED grants. No changes to capital policy have been disclosed, but continued R&D investment will affect the financial position.","jir_financial_highlights":"Revenue: 10,000 (Same as prior period)\nOperating loss: -161,406 (Prior interim period -188,439)\nOrdinary loss: -154,495 (Prior interim period -151,226)\nNet loss attributable to owners of parent (interim): -154,997 (Prior interim period -151,728)\nCash and cash equivalents: 3,193,623 (End of previous fiscal year 3,402,705 \u2192 3,193,623)\nEquity ratio: 96.7 (Reference value)","jir_category":"","jir_hashtags":"#RenascienceEarnings, #DrugDevelopment, #AI_MedicalDevice","jir_key_figures":"Revenue: 10,000 thousand yen\nOperating loss: -161,406 thousand yen\nInterim net loss: -154,997 thousand yen","jir_meta_title":"Renascience Inc. Interim Financial Summary for FY Ending March 2027 | Earnings Overview and R5600-series Development Status","jir_meta_description":"Renascience Inc.'s financial summary for the second quarter of the fiscal year ending March 2027. Summary of revenue and profit\/loss, R&D expenses, development progress in oncology and anti-aging areas centered on RS5614, and future strategy.","jir_og_title":"Renascience Inc. Interim Financial Summary FY2027 | Development Strategy and Financial Position","jir_og_description":"Renascience Inc. Q2 financial summary. Revenue was 10 thousand yen, operating loss was 161 million yen. Continued R&D in oncology centered on RS5614 and in anti-aging areas.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57877,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-149194","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n